A newly developed fluorine-18-labeled somatostatin peptide produced high-contrast PET images of neuroendocrine tumors in mice, with strong tumor uptake and excellent stability.
>5× tumor-to-muscle ratioThe tracer accumulated more than five times as much in tumors as in surrounding muscle tissue
What the researchers found
A new fluorine-18-labeled somatostatin analog ([Al18F]NODA-MPAA-HTA) was synthesized with 60–80% radiochemical yield and >95% purity. It binds all five somatostatin receptor subtypes and showed a binding affinity of 8.77 nM for SSTR2. In mice bearing SSTR2-positive tumors, the tracer achieved tumor-to-muscle uptake ratios greater than 5-fold, producing high-contrast PET images with no defluorination detected in vivo.
Why it matters
Current PET imaging of neuroendocrine tumors primarily uses gallium-68-labeled somatostatin analogs, but fluorine-18 has advantages — its longer half-life (110 minutes vs. 68 minutes) and easier production could make these scans more widely available. This new tracer targets all five somatostatin receptor subtypes rather than just SSTR2, potentially improving detection of tumors that express different receptor profiles.
How the study worked
The researchers designed a peptide-based radiotracer by conjugating fluorine-18 to a modified KE108 somatostatin analog using aluminum-fluoride chelation chemistry. They tested its stability in saline and bovine serum, measured cellular uptake and receptor binding affinity in SSTR2-expressing cells, and performed micro-PET imaging and biodistribution studies in tumor-bearing mice.
What this study cannot tell us
This is a preclinical study conducted only in cell lines and mice — no human imaging data were collected. The tumor model used cells engineered to overexpress SSTR2, which may not reflect the heterogeneous receptor expression found in actual patient tumors. Long-term toxicity and pharmacokinetics in larger animal models were not assessed.
How to read the evidence
This is a preclinical development study demonstrating proof-of-concept in cell lines and a mouse tumor model. It represents early-stage evidence that has not yet been tested in human subjects.
When this study was published
Published in 2024, this is very recent work at the frontier of peptide radiopharmaceutical development. The tracer has not yet entered clinical trials.
The bigger picture
Peptide-based radiotracers are central to the 'theranostics' revolution in oncology, where the same peptide scaffold is used for both imaging and targeted radiation therapy. Developing fluorine-18 versions of somatostatin analogs could democratize PET imaging for neuroendocrine tumors by reducing dependence on cyclotron-adjacent gallium-68 generators, making these critical scans available at more hospitals.
Questions still open
- How will this tracer perform in human patients whose tumors have variable somatostatin receptor expression across all five subtypes?
- Could the same peptide scaffold be adapted for therapeutic use with a different radionuclide, enabling a true theranostic pair?
- How does this tracer's image quality compare directly to gallium-68 DOTATATE in head-to-head preclinical studies?
Common questions
Why use fluorine-18 instead of gallium-68 for PET imaging?
What are somatostatin receptors and why do they matter for tumor imaging?
Read the original research
18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs).
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 193, 106671
Citation
Gao, Fei; Zhang, Yunhan; Chen, MengYi; Song, ZhiHao; Dong, RuiLin; Qiu, ShanShan; Shen, Chen; Huang, XiaoYan; Geng, Hao; Cheng, Weihua; Hu, Ji. (2024). 18F-labeled somatostatin analogs for somatostatin receptors (SSTRs) targeted PET imaging of neuroendocrine tumors (NETs).. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 193, 106671. https://doi.org/10.1016/j.ejps.2023.106671